LENSAR (NASDAQ:LNSR - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $13.40 million for the quarter. LENSAR has set its FY 2025 guidance at EPS and its Q1 2025 guidance at EPS.
LENSAR (NASDAQ:LNSR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.40). LENSAR had a negative net margin of 34.03% and a negative return on equity of 49.02%. The company had revenue of $16.73 million during the quarter, compared to the consensus estimate of $14.95 million.
LENSAR Stock Performance
Shares of NASDAQ LNSR opened at $14.05 on Thursday. The stock has a 50 day moving average price of $13.80 and a 200 day moving average price of $10.04. The stock has a market capitalization of $165.64 million, a PE ratio of -9.62 and a beta of 0.56. LENSAR has a 52 week low of $2.95 and a 52 week high of $17.31.
Analysts Set New Price Targets
Several research firms recently weighed in on LNSR. BTIG Research cut shares of LENSAR from a "strong-buy" rating to a "hold" rating in a research note on Monday, March 24th. Lake Street Capital reaffirmed a "hold" rating and set a $15.00 price target (down previously from $16.00) on shares of LENSAR in a report on Monday, March 24th.
Read Our Latest Research Report on LNSR
About LENSAR
(
Get Free Report)
LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LENSAR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list.
While LENSAR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
